newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agre